RT Journal Article
SR Electronic
T1 Advancing Sewage Sample Surveillance with OmiCrisp: A CRISPR-Based Platform for Variant-Specific SARS-CoV-2 Detection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.05.28.24307854
DO 10.1101/2024.05.28.24307854
A1 Kruthika, BS
A1 Roy, Bidipta
A1 Shridhar, Varsha
A1 Gupta, Vaijayanti
A1 Chandru, Vijay
A1 Arora, Reety
YR 2024
UL http://medrxiv.org/content/early/2024/05/28/2024.05.28.24307854.abstract
AB The detection and differentiation of SARS-CoV-2 variants are vital for disease management and timely patient isolation. Although qRT-PCR has been the standard method, our OmiCrisp assay has shown superior results in identifying Omicron and non-Omicron variants. The World Health Organization advises ongoing sewage surveillance to monitor community viral load, accounting for both symptomatic and asymptomatic individuals. In a previous study, our CRISPR-based assay achieved a 99% concordance with qRT-PCR in sewage samples. We expanded this research by analyzing 182 sewage samples from Bangalore during the JN.1 (BA.2.86.1.1) variant outbreak. Using the OmiCrisp assay, 153 samples (84.06%) tested positive, 16 (8.79%) were negative, and 13 (7.14%) were low positive. Results indicated a significant reduction in positivity rates by the end of the study. The OmiCrisp assay thus proves to be an accurate and effective tool for community-wide surveillance of SARS-CoV-2 variants.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSelf-funded.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript